Return to work in younger patients with brain metastases who survived for 2 years or more
Journal of Neuro-Oncology · 2025
DOI: 10.1007/s11060-024-04840-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2025. Verfasst von Carsten Nieder und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Palliative Medicine, Nordland Hospital Trust, 8092, Bodø, Norway. carsten.nieder@nlsh.no. Hauptthemen laut MEDLINE: Brain Neoplasms, Return to Work. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UiT The Arctic University of Norway.
Abstract (Originalsprache)
Purpose
The study’s purpose was to analyze return to work and other long-term outcomes in younger patients with newly diagnosed brain metastases, treated before they reached legal retirement age, i.e. younger than 65 years.
Methods
We included patients who survived greater than 2 years after their first treatment, regardless of approach (systemic therapy, neurosurgical resection, whole-brain or stereotactic radiotherapy). The primary endpoint was the proportion of patients who worked 2 years after their initial treatment for brain metastases. Outcomes beyond the 2-year cut-off were also abstracted from comprehensive electronic health records, throughout the follow-up period.
Results
Of 455 patients who received active therapy for brain metastases, 62 (14%) survived for > 2 years. Twenty-eight were younger than 65 years. The actuarial median survival was 81 months and the 5-year survival rate 53%. For patients alive after 5 years, the 10-year survival rate was 54%. At diagnosis, 25% of patients (7 of 28) were permanently incapacitated for work/retired. Of the remaining 21 patients, 33% did work 2 years later. However, several of these patients went on to receive disability pension afterwards. Eventually, 19% continued working in the longer run. Younger age, absence of extracranial metastases, presence of a single brain metastasis, and Karnofsky performance status 90–100 were common features of patients who worked after 2 years.
Conclusion
Long-term survival was achieved after vastly different therapeutic approaches, regarding both upfront and sequential management. Many patients required three or more lines of brain-directed treatment. Few patients continued working in the longer run.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology and Palliative Medicine, Nordland Hospital Trust, 8092, Bodø, Norway. carsten.nieder@nlsh.no.
- Department of Clinical Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway. carsten.nieder@nlsh.no.
- Department of Oncology and Palliative Medicine, Nordland Hospital Trust, 8092, Bodø, Norway.
- Department of Clinical Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway.
- Department of Quality and Health Technology, Faculty of Health Sciences, SHARE - Center for Resilience in Healthcare, University of Stavanger, Stavanger, Norway.
Förderung
- UiT The Arctic University of Norway
Zitieren
APA
Nieder, C., Aanes, S. G., Stanisavljevic, L., Mannsåker, B., & Haukland, E. C. (2025). Return to work in younger patients with brain metastases who survived for 2 years or more. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04840-x
Vancouver
Nieder C, Aanes SG, Stanisavljevic L, Mannsåker B, Haukland EC. Return to work in younger patients with brain metastases who survived for 2 years or more. Journal of Neuro-Oncology. 2025. doi:10.1007/s11060-024-04840-x
BibTeX
@article{Nieder2025,
author = {Nieder, Carsten and Aanes, Siv Gyda and Stanisavljevic, Luka and Mannsåker, Bård and Haukland, Ellinor Christin},
title = {Return to work in younger patients with brain metastases who survived for 2 years or more},
journal = {Journal of Neuro-Oncology},
year = {2025},
doi = {10.1007/s11060-024-04840-x}
}
EUVIMED